HAP Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

HAP Trading’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,600	Closed	-$395K	–	701
2024 Q4	$395K	Hold	4,600	–	–	0.03%	228
2024 Q3	$586K	Sell	4,600 -5,300	-54%	-$1.38M	0.07%	173
2024 Q2	$556K	Sell	9,900 -46,500	-82%	-$7.34M	0.07%	177
2024 Q1	$394K	Buy	+56,400	New	+$9.41M	0.05%	211
2023 Q4	–	Sell	-25,700	Closed	-$34K	–	949
2023 Q3	$34K	Buy	+25,700	New	+$4.9M	0.01%	586
2018 Q2	–	Sell	-34,400	Closed	-$21K	–	971
2018 Q1	$21K	Buy	34,400 +8,000	+30%	+$1.03M	﹤0.01%	759
2017 Q4	$30K	Sell	26,400 -152,700	-85%	-$19.2M	﹤0.01%	736
2017 Q3	$3.82M	Buy	+179,100	New	+$15.3M	0.18%	108
2016 Q4	–	Sell	-13,100	Closed	-$33K	–	982
2016 Q3	$33K	Sell	13,100 -36,800	-74%	-$2.6M	﹤0.01%	766
2016 Q2	$36K	Buy	+49,900	New	+$3.14M	﹤0.01%	646
2015 Q3	–	Sell	-10,000	Closed	-$124K	–	1031
2015 Q2	$124K	Buy	+10,000	New	+$1.2M	0.01%	545
2014 Q2	–	Sell	-92,500	Closed	-$40K	–	933
2014 Q1	$40K	Buy	+92,500	New	+$7.16M	﹤0.01%	817

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HAP Trading's ALNY Position: Q2 2024 in Review

HAP Trading sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 23,798 shares — an estimated $3.76M sold.

HAP Trading first reported a position in ALNY in Q3 2023 and held it in 2 quarters. The position peaked at $3.56M in Q1 2024. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

HAP Trading reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
HAP Trading sold 23,798 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $3.76M.
HAP Trading first reported a position in Alnylam Pharmaceuticals in Q3 2023 and held it in 2 quarters.
HAP Trading's Alnylam Pharmaceuticals position peaked at $3.56M in Q1 2024.
521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.